AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. (Q55463295)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

title

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

main subject

adaptive radiation therapy

0 references

phase III clinical trial

0 references

bevacizumab

1 reference

based on heuristic

inferred from title

temozolomide

0 references

glioblastoma

1 reference

based on heuristic

inferred from title

author

Olivier Chinot

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

Timothy F. Cloughesy

series ordinal

8

object named as

T Cloughesy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

author name string

T de La Motte Rouge

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

N Moore

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

A Zeaiter

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

A Das

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

H Phillips

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

Z Modrusan

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

language of work or name

English

0 references

publication date

14 March 2011

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

published in

Advances in Therapy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

volume

28

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

page(s)

334-340

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

cites work

Glioblastoma multiforme: a review of where we have been and where we are going

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Epidemiology of brain tumors.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Vascular endothelial growth factor: basic science and clinical progress

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

retrieved

21 January 2018

Identifiers

DOI

10.1007/S12325-011-0007-3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

Dimensions Publication ID

1037365997

0 references

PubMed publication ID

21432029

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21432029

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

retrieved

26 January 2020

ResearchGate publication ID

50833352

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55463295&oldid=2212782396"